​

Maravai LifeSciences (MRVI) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MRVI Stock Forecast

Maravai LifeSciences (MRVI) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $19.00, with a high of $25.00 and a low of $10.00. This represents a 284.62% increase from the last price of $4.94.

- $5 $10 $15 $20 $25 High: $25 Avg: $19 Low: $10 Last Closed Price: $4.94

MRVI Stock Rating

Maravai LifeSciences stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (62.50%), 3 Hold (37.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 3 5 Strong Sell Sell Hold Buy Strong Buy

MRVI Price Target Upside V Benchmarks

TypeNameUpside
StockMaravai LifeSciences284.62%
SectorHealthcare Stocks 25.00%
IndustryBiotech Stocks 63.52%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$10.00
Last Closing Price$4.94$4.94$4.94
Upside/Downside--102.43%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 25186-116
Jan, 25186-116
Dec, 24186-116
Nov, 24696--21
Oct, 24694--19
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 09, 2024Catherine SchulteRobert W. Baird$10.00$8.8712.74%102.43%
Dec 14, 2022Deutsche Bank$25.00$15.0366.33%406.07%
Dec 07, 2022RBC Capital$22.00$12.5076.00%345.34%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 19, 2024GuggenheimNeutralinitialise
Oct 08, 2024UBSUnderperformUnderperformhold
Aug 27, 2024Wells FargoOverweightinitialise
Aug 13, 2024Morgan StanleyOverweightEqual-Weightdowngrade
Aug 08, 2024UBSNeutralNeutralhold
Jun 03, 2024JefferiesBuyBuyhold
May 29, 2024RBC CapitalOutperformOutperformhold
Feb 23, 2024William BlairOutperformOutperformhold
Dec 12, 2023Bank of America SecuritiesBuyupgrade
Jan 05, 2023UBSNeutraldowngrade

Financial Forecast

EPS Forecast

$-1 $0 $1 $2 $3 $4 $5 $6 $7 $8 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.43$1.82$1.92$-0.90-----
Avg Forecast$0.36$1.52$1.79-$-0.08$-0.07$-0.02$0.01$-0.03
High Forecast$0.35$1.47$1.59-$-0.10$-0.16$-0.02$0.01$-0.03
Low Forecast$0.37$1.57$1.97-$-0.07$0.01$-0.01$0.01$-0.02
Surprise %1963.89%19.74%7.26%------

Revenue Forecast

$200M $350M $500M $650M $800M $950M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$284.10M$799.24M$883.00M$288.94M-----
Avg Forecast$275.25M$779.14M$883.43M$279.27M$260.15M$265.12M$294.94M$342.21M$359.90M
High Forecast$269.36M$762.46M$805.34M$274.21M$259.90M$233.46M$293.39M$342.21M$316.39M
Low Forecast$282.14M$798.64M$949.75M$281.86M$260.50M$280.96M$296.49M$342.21M$390.57M
Surprise %3.21%2.58%-0.05%3.46%-----

Net Income Forecast

$-150M $-20M $110M $240M $370M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$76.89M$469.25M$490.66M$-119.03M-----
Avg Forecast$46.88M$134.92M$209.76M$-119.03M$-11.08M$-9.49M$-2.05M$976.11K$-3.30M
High Forecast$45.57M$107.94M$167.81M$-142.83M$-13.30M$-20.70M$-2.58M$842.24K$-3.66M
Low Forecast$48.40M$161.90M$251.71M$-95.22M$-8.86M$1.73M$-1.52M$1.11M$-2.78M
Surprise %64.02%247.80%133.92%------

MRVI Forecast FAQ

Is Maravai LifeSciences stock a buy?

Maravai LifeSciences stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Maravai LifeSciences is a favorable investment for most analysts.

What is Maravai LifeSciences's price target?

Maravai LifeSciences's price target, set by 8 Wall Street analysts, averages $19 over the next 12 months. The price target range spans from $10 at the low end to $25 at the high end, suggesting a potential 284.62% change from the previous closing price of $4.94.

How does Maravai LifeSciences stock forecast compare to its benchmarks?

Maravai LifeSciences's stock forecast shows a 284.62% upside, outperforming the average forecast for the healthcare stocks sector (25.00%) and outperforming the biotech stocks industry (63.52%).

What is the breakdown of analyst ratings for Maravai LifeSciences over the past three months?

  • February 2025: 6.25% Strong Buy, 50.00% Buy, 37.50% Hold, 0% Sell, 6.25% Strong Sell.
  • January 2025: 6.25% Strong Buy, 50.00% Buy, 37.50% Hold, 0% Sell, 6.25% Strong Sell.
  • December 2024: 6.25% Strong Buy, 50.00% Buy, 37.50% Hold, 0% Sell, 6.25% Strong Sell.

What is Maravai LifeSciences’s EPS forecast?

Maravai LifeSciences's average annual EPS forecast for its fiscal year ending in December is $-0.08 for 2024, a -91.11% decrease from the reported $-0.9 in 2023. The prediction for 2025 is $-0.07, $-0.02 for 2026, $0.01 for 2027, and $-0.03 for 2028.

What is Maravai LifeSciences’s revenue forecast?

Maravai LifeSciences's average annual revenue forecast for its fiscal year ending in December is $260.15M for 2024, a -9.97% decrease from the reported $288.94M in 2023. The forecast for 2025 is $265.12M, $294.94M for 2026, $342.21M for 2027, and $359.9M for 2028.

What is Maravai LifeSciences’s net income forecast?

For its fiscal year ending in December, Maravai LifeSciences's average annual net income forecast is $-11.08M for 2024, reflecting a -90.69% decrease from the reported $-119M in 2023. The projection for 2025 is $-9.488M, $-2.052M for 2026, $976.11K for 2027, and $-3.298M for 2028.